NEO - NeoGenomics Inc. (NEO) Q1 2024 Earnings Call Transcript
2024-04-30 14:11:03 ET
NeoGenomics, Inc. (NEO)
Q1 2024 Earnings Conference Call
April 30, 2024, 08:30 AM ET
Company Participants
Kendra Sweeney - VP of IR
Chris Smith - CEO
Jeff Sherman - CFO
Warren Stone - Chief Commercial Officer
Melody Harris - Chief Operations Officer and President, Informatics
Ali Olivo - EVP, General Counsel and Business Development
Conference Call Participants
Mark Massaro - BTIG
Puneet Souda - Leerink Partners
Dan Brennan - TD Cowen
Andrew Brackman - William Blair
Tejas Savant - Morgan Stanley
Mike Matson - Needham and Company
John Kim - Bank of America
Mason Carrico - Stephens
Prashant Kota - Goldman Sachs
Andrew Cooper - Raymond James
Presentation
Operator
Welcome to the NeoGenomics First Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Please note, this call is being recorded, and an audio replay will be available on the company's website.
Kendra Sweeney, Vice President of Investor Relations, you may begin your conference.
Kendra Sweeney
Thank you, Holly. Good morning, everyone, and welcome to the NeoGenomics first quarter 2024 financial results call.
With me today to discuss the results are Chris Smith, Chief Executive Officer; and Jeff Sherman, Chief Financial Officer. Additional members of the management team are available for Q&A including Warren Stone, Chief Commercial Officer; Melody Harris, Chief Operations Officer and President of Informatics; and Ali Olivo, Executive Vice President, General Counsel and Business Development.
This call is being simultaneously webcast. We will be referring to a slide presentation that has been posted to the Investors tab on our website at ir.neogenomics.com.
Starting on Slide 2, during this call, we'll be making forward-looking statements regarding our anticipated future performance. We caution you that such statements reflect our best judgment based on factors currently known to us, and that actual events, or results could differ materially. Please refer to our most recent forms 10-K, 10-Q, and 8-K we filed with the SEC, to identify important risks and other factors that may cause our actual results to differ materially from the forward-looking statements....
NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript